• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >MEDI 4736 (durvalumab) in non-small cell lung cancer
【24h】

MEDI 4736 (durvalumab) in non-small cell lung cancer

机译：Medi 4736（Durvalumab）在非小细胞肺癌中

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC. Other notable PD-L1 inhibitors under development include avelumab and durvalumab.Areas covered: This article reviews literature on durvalumab development, from the preclinical data to the results of phase III clinical trials, whether published or presented at international scientific conferences. Ongoing clinical trials were also reviewed.Expert opinion: Early phase trials of durvalumab monotherapy (and in combination) have demonstrated activity in advanced NSCLC patients and it has demonstrated a good safety profile. The authors believe that durvalumab will likely play an important role in future treatment strategies for NSCLC. The PACIFIC trial assessing durvalumab after standard chemoradiotherapy for locally advanced NSCLC has already met its primary endpoint and the potential of durvalumab will be reinforced if phase III randomized studies of first-line (MYSTIC trial) and second or subsequent (ARCTIC trial) lines of therapy demonstrate superiority over the current standard of care.
机译：简介：免疫检查点抑制剂（ICI）现在是晚期非小细胞肺癌（NSCLC）患者的治疗选择。 ICI，例如PD-1抑制剂Nivolumab和Pembrolizumab和PD-L1抑制剂atezolizumab已被销售用于治疗预期NSCLC的预处理患者。正在开发的其他值得注意的PD-L1抑制剂包括Avelumab和Durvalumab.areas涵盖：本文介绍了Durvalumab开发的文献，从临床前数据到III期临床试验的结果，无论是否在国际科学会议上发表或提交。还审查了持续的临床试验.Pert意见：Durvalumab单药治疗的早期阶段试验（以及组合）在先进的NSCLC患者中表现出活性，并证明了良好的安全性。作者认为，Durvalumab可能在NSCLC的未来治疗战略中发挥重要作用。在局部高级NSCLC的标准化学大学治疗后评估Durvalumab的太平洋试验已经达到了其主要终点，如果III阶段对第一线（神秘试验）和第二种或之后（Arctic试验）治疗的阶段的随机研究，将加强Durvalumab的潜力在目前的护理标准上表现出优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号